Top Banner
1 A continued FDA Concern about Imaging Based Drug Trials Society of Nuclear Medicine Albuquerque, Feb 1-2, 2009 Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products Office of New Drugs
9

Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

Jan 01, 2016

Download

Documents

linus-rosario

A continued FDA Concern about Imaging Based Drug Trials Society of Nuclear Medicine Albuquerque, Feb 1-2, 2009. Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products Office of New Drugs. Good science!. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

1

A continued FDA Concern about Imaging Based Drug Trials

Society of Nuclear MedicineAlbuquerque, Feb 1-2, 2009

Orhan H Suleiman MS PhD, FAAPM

Senior Science Policy Adviser

Office of Oncology Drug Products

Office of New Drugs

Page 2: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

2

Good science!Good scientific principles are essential for

good imaging based trials:

1. Standardize imaging equipment;

2. standardize imaging acquisition, processing, and display protocol;

3. standardize readers.

4. Know the uncertainties- 1%, 5%, 20%, 50%, 100%, ?

Page 3: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

3

In order to detect change clinically, you need to assure the standard image remains constant.

Page 4: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

4

Conduct Quality Control Testing

In order to assure that the images are being produced consistently over time you should…

Quality control test, with a phantom, before, during, and at the end of the trial, which should assure consistency in equipment performance! This includes the use of the same software and imaging technique.

Page 5: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

5

History of Imaging Criteria

World Health Organization (1970’s)

Response Evaluation Criteria in Solid Tumors – RECIST (2000, 2008)

3-dimensional volumetric analysis (current)

Page 6: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

6

-50

-40

-30

-20

-10

0

% Change

1 2

Measurement technique

Percentage Change in the measurement

RECIST Volume

- 3.5 %

- 32 %

baseline

30 days

Diameter = 17.7 mm

Diameter = 17.1 mm

Volume = 886 mm3

Volume = 525 mm3

RECIST vs. Volumetrics

Bensheng Zhao, MSKCC

Page 7: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

7

“Calibrate” Human Readers

Train the qualified readers, prospectively!

Use standard images to “calibrate” readers, either physically together, or with a detailed protocol. This should minimize adjudication.

Protocol should specify data collection, viewing conditions, image scoring and other criteria.

Page 8: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

8

In closing…

Quality control testing with appropriate test phantoms must be used on all imaging equipment used to generate clinical images during the trial.

Ultimately successful clinical trials depend on using good science for the entire trial (drug, equipment, image, analysis).

Page 9: Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office of Oncology Drug Products

9

FDA10903 New Hampshire Ave

Silver Spring, Maryland 20993